Redx confirms changes to Board composition

Dr. Claire Catherinet to replace Dr. Joe Anderson as Non-Executive Director representing Sofinnova

Alderley Park, UK, 14 May 2024 Redx (JPJ:REDX), the clinical-stage, small molecule biotechnology company confirms the appointment of Dr. Claire Catherinet to the Board of Directors, effective 10 May 2024. Dr. Catherinet will represent Sofinnova Crossover I SLP, one of the Company’s major shareholders, replacing Dr. Joe Anderson.

Dr. Catherinet is a Senior Associate at Sofinnova Partners – Crossover Strategy. Dr. Catherinet joined Sofinnova in 2021, having previously been an analyst on the Life Sciences team at Andera Partners. Dr. Catherinet has a PhD in Hemato-Oncology from Paris Diderot University, an MSc from Agrocampus Ouest and a degree in Biopharmaceutical Management from ESCP Business School. Her research has been published in journals such as Nature Communications and Cancer Cell.

Dr. Jane Griffiths, Chair of the Board, commented: “We are delighted to welcome Claire to the Board of Directors. Her experience working with biotech companies, combined with her scientific background, will be invaluable to Redx as we continue to progress our pipeline of differentiated drug candidates. I would also like to thank Joe for his insightful contributions over the past year and wish him well for the future.”

For further information, please contact:

Redx Pharma Limited UK Headquarters

Caitlin Pearson, Head of Communications

ir@redxpharma.com

T: +44 (0)1625 469 918

FTI Consulting

Simon Conway/Ciara Martin

T: +44 (0)203 727 1000

About Redx Pharma Limited

Redx (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohns disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development. The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which include the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.